Humana Inc. (HUM) Receives Consensus Recommendation of “Buy” from Analysts
Shares of Humana Inc. (NYSE:HUM) have received a consensus rating of “Buy” from the twenty-four research firms that are covering the firm, Marketbeat reports. Twelve equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $252.95.
Several equities research analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Humana from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 17th. BMO Capital Markets assumed coverage on shares of Humana in a research note on Monday, October 16th. They set an “outperform” rating and a $300.00 price objective for the company. Jefferies Group LLC reiterated a “hold” rating and set a $257.00 price objective on shares of Humana in a research note on Friday, October 13th. Royal Bank Of Canada reiterated a “hold” rating and set a $245.00 price objective on shares of Humana in a research note on Tuesday, October 10th. Finally, ValuEngine downgraded shares of Humana from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th.
WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/22/humana-inc-hum-receives-consensus-recommendation-of-buy-from-analysts-2.html.
In other Humana news, VP Timothy S. Huval sold 7,803 shares of Humana stock in a transaction on Friday, September 1st. The shares were sold at an average price of $258.14, for a total value of $2,014,266.42. Following the completion of the transaction, the vice president now owns 8,831 shares of the company’s stock, valued at $2,279,634.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP M Todoroff Christopher sold 22,935 shares of Humana stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $252.52, for a total transaction of $5,791,546.20. Following the completion of the transaction, the vice president now directly owns 24,001 shares of the company’s stock, valued at approximately $6,060,732.52. The disclosure for this sale can be found here. Insiders sold 55,595 shares of company stock valued at $14,133,706 in the last ninety days. 0.80% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in shares of Humana by 1.6% during the second quarter. Vanguard Group Inc. now owns 9,892,635 shares of the insurance provider’s stock worth $2,380,366,000 after purchasing an additional 157,868 shares in the last quarter. FMR LLC increased its stake in shares of Humana by 29.3% during the second quarter. FMR LLC now owns 6,530,063 shares of the insurance provider’s stock worth $1,571,264,000 after purchasing an additional 1,479,210 shares in the last quarter. State Street Corp increased its stake in shares of Humana by 1.4% during the first quarter. State Street Corp now owns 6,274,811 shares of the insurance provider’s stock worth $1,293,487,000 after purchasing an additional 84,716 shares in the last quarter. Capital Research Global Investors increased its stake in shares of Humana by 9.7% during the second quarter. Capital Research Global Investors now owns 3,907,333 shares of the insurance provider’s stock worth $940,182,000 after purchasing an additional 346,069 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Humana by 1.5% during the second quarter. Renaissance Technologies LLC now owns 2,731,100 shares of the insurance provider’s stock worth $657,157,000 after purchasing an additional 39,400 shares in the last quarter. 95.11% of the stock is owned by institutional investors.
Humana (NYSE:HUM) opened at 245.81 on Friday. The company has a 50-day moving average of $245.62 and a 200-day moving average of $236.63. Humana has a one year low of $165.03 and a one year high of $259.76. The stock has a market capitalization of $35.52 billion, a price-to-earnings ratio of 20.22 and a beta of 0.86.
Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The business had revenue of $13.53 billion during the quarter, compared to the consensus estimate of $13.61 billion. During the same period in the previous year, the firm posted $2.30 earnings per share. On average, equities analysts forecast that Humana will post $11.57 EPS for the current fiscal year.
The company also recently disclosed a dividend, which was paid on Monday, October 16th. Shareholders of record on Friday, September 29th were issued a $0.40 dividend. The ex-dividend date of this dividend was Thursday, September 28th. Humana’s payout ratio is 13.06%.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.